Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


XingJie Liang

XingJie Liang

National Center for Nanoscience and Technology of China


Dr. Liang got Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and chief of laboratory of Nanomedicine and Nanosafety, National Center for Nanoscience and Technology of China. Dr. Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research and Union for International Cancer Control. Dr. Liang is current editorial board member of 《Advances in Nano Research》 《Acta Biophysica Sinica》《Journal of Nanomaterials》and 《Current Nanoscience》, guest editor of 《Biotechnology Advances》. Dr. Liang was honored with 2004、2005、2006 “Fellows Award for Research Excellence” in NIH; “Special Government Allowances” by Department of State, 2011; “National Distinguished Young Scholars” by NSFC; and “Young Pharmaceutics Scholar” by CPA, 2012.

Research Interest

His research interests are in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vivo, and novel strategies to increase therapeutic effect on cancers and infective diseases. Developing drug delivery strategies for prevention/treatment of AIDS and cancers are current program ongoing in Dr. Liang's lab based on understanding of basic physio-chemical and biological processes of nanomedicine. Most protocols are employed for delivering therapeutic molecules (chemical compounds or nucleic acids) to actively target cells or tissues in vivo to enhance drug safety and efficacy.